The third generation GD2-CAR T cells have an intermediate expression of exhaustion markers compared to the second generation CD28 CAR and the 4-1BB CAR

The third generation GD2-CAR T cells have an intermediate expression of exhaustion markers compared to the second generation CD28 CAR and the 4-1BB CAR. and comparable lysis of both GD2+ sarcoma and neuroblastoma cell lines was evaluated using a 51Cr release assay. Target cells were labeled with 51Cr and incubated with GD2-CAR transduced effector T cells at varying effector-to-target (E:T) ratios. After 8 hours of co-incubation at 37C, supernatant was removed and the amount of 51Cr released into the media was assessed using a Top Count reader. Lysis was calculated as follows: % lysis = [(experimental lysis-spontaneous lysis)/(maximum lysis-spontaneous lysis)] 100%, where maximal lysis was induced by incubation in a 2% Triton X answer. Chemokine production assay G-CSF production by tumor cell lines was evaluated within supernatants by ELISA (R&D Systems). IL8 production by tumor cell lines was evaluated with the MesoScale Discovery Pro-Inflammatory multi-array 96 well system. MDSC suppression assays Where indicated, mice received surgically-implanted subcutaneous ATRA pellets (21 day timed release; 5mg; Innovative Research of America) or sham surgeries LY2157299 one day prior to tumor inoculation. MDSCs were then isolated via CD11b or Ly6G magnetic selection from spleens of tumor-bearing mice 15-20 days after tumor inoculation. Isolated MDSCs were titrated into human T-cell cultures at varying MDSC:T-cell ratios and incubated overnight. For flow-based proliferation assays, human T cells were pre-labeled with CellTrace Violet or CSFE (Invitrogen). Following overnight incubation, either human CD3/CD28 coated stimulatory beads (1:1) or the GD2-CAR anti-idiotype 1A7 antibody (0.5 g/mL; Biological Research Branch of NCI) and a cross-linking anti-mouse F(ab)2 (2.5 g/mL, Jackson Immunoresearch) were added to the co-culture to serve as a proliferation stimulus. After 4-5 addition days of incubation, cells were harvested and proliferation evaluated by either circulation cytometry (percent of divided calculated using FlowJo 9 software, Treestar) or direct cell count measurements. All MDSC suppression assays were conducted in custom RPMI 1640 made up of physiologic levels of L-arginine (150 mM) supplemented with 10% FBS, 50 mM 2-mercaptoethanol, 10 LY2157299 mM HEPES, 100 U/mL penicillin, 100 ug/mL streptomycin, and 1 mM sodium pyruvate. Circulation cytometry and analysis GD2 expression on tumor cell lines was performed using the anti-GD2 (clone 14g2a; Cd19 BD Pharmingen) and compared to isotype controls. T-cell transduction was measured using the 14g2a anti-idiotype, clone 1A7 (Biological Research Branch LY2157299 of NCI) conjugated to Dylight 650 or 488 (Pierce Protein Biology Products). T-cell phenotypes were identified using the following antibodies to human CD4 (clone OKT4; eBioscience), human CD8 (clone RPA-T8; eBioscience), human CD45 (clone H130; eBioscience), human PD-1 (clone eBioJ105, eBioscience), human TIM-3 (clone F35-2E2, eBioscience), and human LAG-3 (clone 3DS223H, eBioscience). MDSCs were evaluated using antibodies to Ly6C (clone HK1.4; eBioscience), Ly6G (clone 1A8; eBioscience), CD11b (clone M1/70; eBioscience). All antibodies were used per manufacturers recommendations. Live/lifeless cells were distinguished with Fixable Viability Dye eFluor 780 or 506 (eBioscience). Circulation cytometry was carried out using FACS Fortessa with FACS Diva software (BD Biosciences) and analyzed by FlowJo LY2157299 9 software (Treestar). Immunohistochemistry Frozen tissue samples were obtained from surgical samples at the time of clinically indicated tumor resection or biopsy after informed consent. Sections were sliced at 5-micron thickness, fixed in chilly acetone for 10 minutes, dried at room heat for 5 minutes, and rehydrated in PBS for 10 minutes. Samples were quenched with endogenous peroxidase block (DAKO) for 10 minutes, washed for 5 minutes, and incubated for 60 moments at 37C with mouse anti-human GD2 (14G2a, Millipore) diluted in DAKOs antibody diluent with background reducing components to a 1:100 concentration. After washing, sections were incubated for 30 minutes in anti-mouse (biotinylated goat anti-mouse IgG, Vector, Burlingame, CA) at a concentration of 2.5 g/mL. Sections were washed with DAKO wash buffer, incubated in DAKO peroxidase substrate answer for 5 minutes, and washed in PBS. The reaction was developed by a 2-5 minute incubation with the of 3-3 diaminobenzidine chromogenic answer (Vector). Slides were then counterstained with hematoxylin, dehydrated with a series of alcohol solutions (50%-100%), followed by three changes of xylene and mounted with Cytoseal XYL (Thermo Scientific). Analysis was performed using standard microscopy. Tumor models and treatment Xenograft studies were performed using NSG mice 6-12 weeks of age. Mice were inoculated with 5 105 or 106 143b, EW8, or Kelly cells either periosteal to the tibia or subcutaneously on day 0. Where noted, tumors were injected with Matrigel (Corning) diluted 1:1 in PBS. Human GD2-CAR transduced or Mock T cells were adoptively transferred 3-5 days later, as indicated in individual experiments. Mice received cytokine support of 1 1 g IL7 (Cytheris Inc.) and 5 g M25 antibody (anti-IL7; Immunex) intraperitoneally three times per week following T-cell transfer (29). All-trans.